All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
CARTITUDE-4 MRD negativity analysis: Cilta-cel for len-refractory MM
Bookmark this article
|
MRD is an increasingly recognized prognostic marker in MM, providing a sensitive measure for response to therapy. Sustained MRD negativity ≥12 months has been associated with longer PFS and OS. As treatment strategies evolve, MRD is under evaluation as a predictor of long-term outcomes in clinical trials for MM.1 During the ASH congress 2024, Rakesh Popat presented the latest data, including an MRD analysis, from the phase III CARTITUDE-4 trial (NCT04181827), which compared cilta-cel with SoC therapy for the treatment of lenalidomide-refractory MM (N = 419).1 |
| Key learnings |
| Among patients evaluable for MRD, 85.6% of those treated in the cilta-cel arm (n = 139) observed MRD negativity at a sensitivity of ×10⁻⁶, compared with 18.6% in the SoC group (n = 102) (OR 28.5; p < 0.0001). |
|
82.1% of patients treated in the cilta-cel arm observed sustained MRD negativity (≥12 months) at a sensitivity of ×10⁻⁵, compared with 25.2% in the SoC group (OR 12.3; p < 0.0001). |
| The 30-month PFS and OS were 93.2% and 97.3%, respectively, in patients treated with cilta-cel who achieved sustained MRD negativity ≥CR. |
| Patients treated with cilta-cel achieved deep (×10⁻⁶) and sustained MRD negativity ≥CR rates, which correlated with prolonged PFS and OS, supporting the prognostic value of MRD negativity in CAR T-cell therapy. |
Abbreviations: CAR, chimeric antigen receptor; cilta-cel, ciltacabtagene autoleucel; CR, complete response; MRD, measurable residual disease; OR, odds ratio; OS, overall survival; PFS, progression-free survival; SoC, standard-of-care.
- Popat R. Ciltacabtagene autoleucel (cilta-cel) vs standard of care (SoC) in patients with lenalidomide (len)-refractory multiple myeloma (MM) after 1–3 lines of therapy: Minimal residual disease (MRD) negativity in the phase 3 CARTITUDE-4 trial. Oral Abstract #1032. Presented at 66th American Society of Hematology Annual Meeting and Exposition; Dec 7–10, 2024; San Diego, US.
Your opinion matters
2 votes - 39 days left ...
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox